Pharma & Biotech Insights, Interviews & Features
Today's issue
Refine Search
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 7 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 31 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences. 20 September 2024
Generics
Swiss pharma giant Novartis intends to localize up to 40 drugs at its Novartis-Neva plant in the Russian St Petersburg region, according to recent statements of vice governor of St Petersburg Sergey Movchan. 19 December 2017
Pharmaceutical
The final Special Report of 2017 comes from Scott Pescatore, the Europe region general manager for rare diseases at Novartis Oncology, and is an overview of how progress has been made, and how more can be achieved, in the orphan medicines space. 19 December 2017
Pharmaceutical
Robert Stewart is to leave his role as chief operating officer of Ireland-incorporated drugmaker Allergan to take the top job at Amneal Pharmaceuticals. 18 December 2017
Pharmaceutical
Pharmaceutical companies in India have been providing scientific insights into the genetic causes and biological processes underlying neurodegenerative diseases, reports The Pharma Letter’s India correspondent. 18 December 2017
Pharmaceutical
In a candid admission, privately-owned German pharma major Boehringer Ingelheim has said that conflicting views over strategy are behind the departure of one of its most senior executives. 18 December 2017
Pharmaceutical
In today’s world, cheap insults from people in high places – whether justified and evidence-backed or not – can do harm to the reputation and market value of pharma firms that can be difficult to repair. 15 December 2017
Generics
Changes to Japan’s drug reimbursement system care are inevitable. The only questions are the extent of changes and when they will be implemented. We should have answers to these questions at year end so they can be implemented in April 2018, says P Reed Maurer, long-time Japan pharma watcher and president of International Alliances Limited in his regular column for The Pharma Letter. 15 December 2017
Biotechnology
Chinese biologics services provider WuXi Biologics (HK: 2269) recently started the operation of a new current Good Manufacturing Practices (cGMP) facility for biologics manufacturing in Wuxi, Jiangsu province, writes Wang Fangqing, The Pharma Letter’s local correspondent. 15 December 2017
Pharmaceutical
Dr Nicola Davies discusses the US Food and Drug Administration’s (FDA) new framework on regenerative medicine that is aimed at spurring innovation in transformative products while ensuring safety and efficacy. 15 December 2017
Pharmaceutical
German pharma major Merck KGaA has appointed from within in naming the head of its newly-created corporate affairs unit. 15 December 2017
Pharmaceutical
In an Expert View piece, Rosanne Kay, partner at international law firm Reed Smith, considers when to escalate matters to an internal investigation, and how best to carry them out. 14 December 2017
Biotechnology
It’s impossible to imagine how many lives antibiotics have saved since penicillin was first synthesized by Alexander Fleming in 1928 - certainly tens, if not hundreds of millions. 14 December 2017
Biotechnology
Clinical-stage US biotech Provectus Biopharmaceuticals has reached a settlement with the US Securities and Exchange Commission (SEC) in connection with investigations relating to two former executives and the company. 13 December 2017
Pharmaceutical
Mundipharma network of independent associated companies has appointed Alberto Martinez as president and chief executive of Mundipharma International, with immediate effect. 13 December 2017
Biotechnology
Swiss pharmaceutical giant Roche, which invested 1.5 billion roubles ($25 million) in the localization of the production of its anti-cancer drug Gaziva/Gazyvaro (obinutuzumab) in Russia in order to participate in public procurements, may not implement its plans, reports The Pharma Letter’s local correspondent. 12 December 2017
Pharmaceutical
It is the third-most common disorder in the world. In the USA, close to 38 million people suffer from it. Globally, the number is a whopping 1 billion. We are talking about migraine, also often referred to as ‘super headaches’ — a condition more prevalent than diabetes, epilepsy, and asthma combined. 11 December 2017
Pharmaceutical
Drug imports by Russia for the period of January-September of 2017 grew for the first time since 2014 and amounted to 108.700 tonnes, which is 6.5% more than in the same period a year ago. 11 December 2017
Generics
The occasion of World AIDS Day was as good as any for India to launch a National Strategic Plan 2017-24, aimed at eradicating HIV/ AIDS by 2030. The country has over 2.1 million people living with HIV, the third largest number of people with HIV in the world, reports The Pharma Letter’s India correspondent. 8 December 2017
Pharmaceutical
Last week, the UK government published its latest annual update on its five year strategy to combat antimicrobial resistance (AMR). AMR, widely accepted as one of the major global challenges of the 21st century, is currently implicated in around 700,000 deaths worldwide, including 50,000 in the USA and Europe alone. 7 December 2017
Biotechnology
French biotech company Cellectis has appointed Professor Stéphane Depil to the role of senior vice president R&D and chief medical officer. 5 December 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze